Related scientific articles (all)

Pathway level alterations rather than mutations in single genes predict response to HER2 targeted therapies in the neo-ALTTO trial.

Authors : Shi W, Jiang T, Nuciforo P, Hatzis C, Holmes E, Harbeck N, Sotiriou C, Peña L, Loi S, Rosa DD, Chia S, Wardley A, Ueno T, Rossari J, Eidtmann H, Armour A, Piccart-Gebhart M, Rimm DL, Baselga J, Pusztai L
Year : 2016
Journal : Ann Oncol
Volume : 28(1)
Pages : 128-35

Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer.

Authors : Ignatiadis M, Zardavas D, Lemort M, Wilke C, Vanderbeeken MC, Dhondt V, de Azambuja E, Gombos A, Lebrun F, Dal Lago L, Bustin F, Maetens M, Ameye L, Veys I, Michiels S, Paesmans M, Larsimont D, Sotiriou C, Nogaret JM, Piccart-Gebhart M, Awada A
Year : 2016
Journal : PLoS One
Volume : 11(7)
Pages : e0154009

Reproductive behaviors and risk of developing breast cancer according to tumor subtype: A systematic review and meta-analysis of epidemiological studies.

Authors : Lambertini M, Santoro L, Del Mastro L, Nguyen B, Livraghi L, Ugolini D, Peccatori FA, Azim HA Jr
Year : 2016
Journal : Cancer Treat Rev
Volume : 49
Pages : 65-76

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.

Authors : Cardoso F, Vant Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, Pierga JY, Brain E, Causeret S, Delorenzi M, Glas AM, Golfinopoulos V, Goulioti T, Knox S, Matos E, Meulemans B, Neijenhuis PA, Nitz U, Passalacqua R, Ravdin P, Rubio IT, Saghatchian M, Smilde TJ, Sotiriou C, Stork L, Straehle C, Thomas G, Thompson AM, van der Hoeven JM, Vuylsteke P, Bernards R, Tryfonidis K, Rutgers E, Piccart-Gebhart M
Year : 2016
Journal : N Engl J Med
Volume : 375(8)
Pages : 717-29

Epstein-Barr Virus Infection of Mammary Epithelial Cells Promotes Malignant Transformation.

Authors : Hu H, Luo ML, Desmedt C, Nabavi S, Yadegarynia S, Hong A, Konstantinopoulos PA, Gabrielson E, Hines-Boykin R, Pihan G, Yuan X, Sotiriou C, Dittmer DP, Fingeroth JD, Wulf GM
Year : 2016
Journal : EBioMedicine
Volume : 9
Pages : 148-60

Managing pregnancy-associated breast cancer: Is more really better?

Authors : Peccatori FA, Azim HA Jr
Year : 2016
Journal : Breast
Volume : 30
Pages : 215-216

Liquid biopsy-based clinical research in early breast cancer: The EORTC 90091-10093 Treat CTC trial.

Authors : Ignatiadis M, Rack B, Rothé F, Riethdorf S, Decraene C, Bonnefoi H, Dittrich C, Messina C, Beauvois M, Trapp E, Goulioti T, Tryfonidis K, Pantel K, Repollet M, Janni W, Piccart-Gebhart M, Sotiriou C, Litiere S, Pierga JY
Year : 2016
Journal : Eur J Cancer
Volume : 63
Pages : 97-104

Frequent incidence of BARD1 truncating mutations in germline DNA from triple negative breast cancer patients.

Authors : De Brakeleer S, De Grève J, Desmedt C, Joris S, Sotiriou C, Piccart-Gebhart M, Pauwels I, Teugels E
Year : 2016
Journal : Clin. Genet.
Volume : 89(3)
Pages : 336-40.

Corrigendum: Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells.

Authors : Ju YS, Tubio JM, Mifsud W, Fu B, Davies HR, Ramakrishna M, Li Y, Yates L, Gundem G, Tarpey PS, Behjati S, Papaemmanuil E, Martin S, Fullam A, Gerstung M, Nangalia J, Green AR, Caldas C, Borg Å, Tutt A, Lee MT, Vant Veer LJ, Tan BK, Aparicio S, Span PN, Martens JW, Knappskog S, Vincent-Salomon A, Børresen-Dale AL, Eyfjörd JE, Myklebost O, Flanagan AM, Foster C, Neal DE, Cooper C, Eeles R, Bova GS, Lakhani SR, Desmedt C, Thomas G, Richardson AL, Purdie CA, Thompson AM, McDermott U, Yang F, Nik-Zainal S, Campbell PJ, Stratton MR
Year : 2016
Journal : Genome Res
Volume : 26
Pages : 717.2

Loss of ARID1A activates ANXA1, which serves as a predictive biomarker for trastuzumab resistance.

Authors : Berns K, Sonnenblick A, Gennissen A, Brohée S, Hijmans ME, Evers B, Fumagalli D, Desmedt C, Loibl S, Denkert C, Neven P, Guo W, Zhang F, Knijnenburg TA, Bosse T, van der Heijden MS, Hindriksen S, Nijkamp W, Wessels LF, Joensuu H, Mills GB, Beijersbergen RL, Sotiriou C, Bernards R
Year : 2016
Journal : Clin Cancer Res
Volume : 22(21)
Pages : 5238-48

Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also.

Authors : Bartlett JM, McConkey CC, Munro AF, Desmedt C, Dunn JA, Larsimont D, O Malley FP, Cameron DA, Earl HM, Poole CJ, Shepherd LE, Cardoso F, Jensen MB, Caldas C, Twelves CJ, Rea DW, Ejlertsen B, Di Leo A, Pritchard KI
Year : 2015
Journal : J. Clin. Oncol.
Volume : 33(15)
Pages : 1680-7

New approaches for improving outcomes in breast cancer in Europe.

Authors : Di Leo A, Curigliano G, Diéras V, Malorni L, Sotiriou C, Swanton C, Thompson A, Tutt A, Piccart-Gebhart M
Year : 2015
Journal : Breast
Volume : 24(4)
Pages : 321-330

No significant viral transcription detected in whole breast cancer transcriptomes.

Authors : Fimereli D, Gacquer D, Fumagalli D, Salgado R, Rothé F, Larsimont D, Sotiriou C, Detours V
Year : 2015
Journal : BMC Cancer
Volume : 15(null)
Pages : 147

RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy.

Authors : Azim HA, Peccatori FA, Brohée S, Branstetter D, Loi S, Viale G, Piccart-Gebhart M, Dougall WC, Pruneri G, Sotiriou C
Year : 2015
Journal : Breast Cancer Res
Volume : 17
Pages : 24

PIK3CA Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2-Targeted Therapies in Breast Cancer.

Authors : Majewski IJ, Nuciforo P, Mittempergher L, Bosma AJ, Eidtmann H, Holmes E, Sotiriou C, Fumagalli D, Jimenez J, Aura C, Prudkin L, Díaz-Delgado MC, de la Peña L, Loi S, Ellis C, Schultz N, de Azambuja E, Harbeck N, Piccart-Gebhart M, Bernards R, Baselga J
Year : 2015
Journal : J. Clin. Oncol.
Volume : 33(12)
Pages : 1334-9

Optimising translational oncology in clinical practice: Strategies to accelerate progress in drug development.

Authors : Stahel R, Bogaerts J, Ciardiello F, De Ruysscher D, Dubsky P, Ducreux M, Finn S, Laurent-Puig P, Peters S, Piccart-Gebhart M, Smit E, Sotiriou C, Tejpar S, van Cutsem E, Tabernero J
Year : 2015
Journal : Cancer Treat Rev
Volume : 41(2)
Pages : 129-135

Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive and Triple-Negative Primary Breast Cancers.

Authors : Denkert C, Von Minckwitz G, Brase JC, Sinn BV, Gade S, Kronenwett R, Pfitzner BM, Salat C, Loi S, Schmitt WD, Schem C, Fisch K, Darb-Esfahani S, Mehta K, Sotiriou C, Wienert S, Klare P, André F, Klauschen F, Blohmer J, Krappmann K, Schmidt M, Tesch H, Kümmel S, Sinn P, Jackisch C, Dietel M, Reimer T, Untch M, Loibl S
Year : 2015
Journal : J. Clin. Oncol.
Volume : 33(9)
Pages : 983-91

Harmonization of the evaluation of tumor infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international TILs-working group 2014.

Authors : Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehne FL, Penault-Llorca F, Perez EA, Thompson EA, Symmans WF, Richardson AL, Brock J, Criscitiello C, Bailey H, Ignatiadis M, Floris G, Sparano J, Kos Z, Nielsen T, Rimm DL, Allison KH, Reis-Filho JS, Loibl S, Sotiriou C, Viale G, Badve S, Adams S, Willard-Gallo K, Loi S
Year : 2015
Journal : Ann Oncol
Volume : 26(2)
Pages : 259-71

CCR 20th Anniversary Commentary: Gene-Expression Signature in Breast Cancer-Where Did It Start and Where Are We Now?

Authors : Gingras I, Desmedt C, Ignatiadis M, Sotiriou C
Year : 2015
Journal : Clin Cancer Res
Volume : 21
Pages : 4743-6

Genomic aberrations in young and elderly  breast cancer patients.

Authors : Azim HA, Nguyen B, Brohée S, Zoppoli G, Sotiriou C
Year : 2015
Journal : BMC Med
Volume : 13
Pages : 266